GARDASIL
GARDASIL
Discontinued
DIN Number
02283190
Drug Class
Human
Market Date
Aug 16, 2006
Company
HC
Merck Canada Inc
Product Information
Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.
Product Details
Health Canada regulatory and product classification information
Regulatory Identifiers
DIN Number02283190
AIG Number0451650001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Schedule D
A
ATC Code
J07BM01 PAPILLOMAVIRUS (HUMAN TYPES 6,11,16,18)
Product Specifications
Dosage FormSuspension
Route of AdministrationIntramuscular
AHFS Classification80:12.00
Health Canada Classification
ACTIVE INGREDIENTS (4)
RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 11 L1 PROTEINActive
Strength: 40 MCG / 0.5 ML
Monograph: RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 11 L1 PROTEIN
RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEINActive
Strength: 40 MCG / 0.5 ML
Monograph: RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN
RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEINActive
Strength: 20 MCG / 0.5 ML
Monograph: RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN
RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 6 L1 PROTEINActive
Strength: 20 MCG / 0.5 ML
Monograph: RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 6 L1 PROTEIN